These findings suggest that MR blockade with spironolactone may exert additive or synergistic effects when combined with antioxidant therapy in MASLD, particularly with respect to insulin resistance and noninvasive markers of hepatic inflammation and steatosis [51]. This evidence concerns the gene NR3C2 and Insulin resistance.